| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 500mg |
|
||
| 1g | |||
| Other Sizes |
| Targets |
As a click chemistry reagent, Bz-(Me)Tz-NHS does not have a defined biological target. Its role is to serve as a chemical tool for bioorthogonal labeling and bioconjugation. The methyltetrazine group enables fast and selective IEDDA reactions with TCO-containing molecules. The NHS ester allows for conjugation to primary amines on proteins or antibodies, enabling targeted delivery and labeling applications.
|
|---|---|
| ln Vitro |
In cell-free biochemical systems, Bz-(Me)Tz-NHS reacts with TCO-containing molecules via the IEDDA reaction. The NHS ester reacts with primary amines on proteins or antibodies to form stable conjugates. The compound's reactivity can be assessed using mass spectrometry, HPLC, or fluorescence assays. The IEDDA reaction is fast and selective, making it suitable for bioorthogonal labeling applications.
|
| ln Vivo |
This compound does not exhibit direct cellular activity as it is a chemical reagent for bioconjugation. Biomolecules labeled with Bz-(Me)Tz-NHS can be delivered to cells for various functional studies. The methyltetrazine group allows for subsequent IEDDA labeling with TCO-containing molecules within cells. The compound is used for live-cell imaging, targeted delivery, and bioconjugation applications.
|
| Enzyme Assay |
The cell-free assay for this compound involves conjugation reactions between the NHS ester and primary amines on proteins or antibodies. The reaction is typically performed in aqueous buffer at pH 7.4-8.5 for 1-4 hours at room temperature or 4°C. The efficiency of conjugation is assessed by mass spectrometry, SDS-PAGE, or HPLC analysis. The IEDDA reaction with TCO-containing molecules can be assessed by mass spectrometry or fluorescence assays.
|
| Cell Assay |
No cell-based experimental protocols are directly applicable to Bz-(Me)Tz-NHS as it is a chemical synthesis reagent. Biomolecules labeled with this compound can be evaluated in cell culture experiments. Typical protocols include treating cells with labeled antibodies or proteins and assessing binding, uptake, and function. The compound can be used for live-cell imaging and targeted delivery applications.
|
| Animal Protocol |
Bz-(Me)Tz-NHS is not administered to animals as it is a chemical reagent for labeling. Biomolecules labeled with this compound may be evaluated in animal models for various applications. Typical studies involve administration of labeled biomolecules to animals via appropriate routes. The methyltetrazine group can be used for in vivo IEDDA labeling if suitable conditions are available.
|
| ADME/Pharmacokinetics |
As a chemical reagent, Bz-(Me)Tz-NHS does not have established pharmacokinetic properties. The compound is used in vitro for bioconjugation and labeling. Its stability, solubility, and reactivity are relevant for its use in chemical biology. The compound is typically stored at low temperatures for research use. It is not intended for therapeutic use.
|
| Toxicity/Toxicokinetics |
The compound is not intended for therapeutic use and lacks established toxicity profiles. Standard laboratory safety precautions should be observed when handling this chemical reagent. The compound is for research use only and is not for human therapeutic applications.
|
| References |
[1]. Jolita Seckute, et al. Rapid oligonucleotide-templated fluorogenic tetrazine ligations. Nucleic Acids Res. 2013 Aug;41(15):e148.
|
| Additional Infomation |
Bz-(Me)Tz-NHS is a research-grade chemical supplied for click chemistry and bioconjugation applications. It is not an approved pharmaceutical and has no clinical trial history. The compound is a third-generation Click-Linker for copper-free click conjugation. This product is intended for research use only.
|
| Molecular Formula |
C19H20N6O5
|
|---|---|
| Exact Mass |
412.149
|
| CAS # |
1454558-58-7
|
| PubChem CID |
89856969
|
| Appearance |
Purple to purplish red solid powder
|
| LogP |
-1
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
30
|
| Complexity |
627
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(ON1C(=O)CCC1=O)(=O)CCCC(NCC1=CC=C(C2=NN=C(C)N=N2)C=C1)=O
|
| InChi Key |
SAFWEESCGQHGHJ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H20N6O5/c1-12-21-23-19(24-22-12)14-7-5-13(6-8-14)11-20-15(26)3-2-4-18(29)30-25-16(27)9-10-17(25)28/h5-8H,2-4,9-11H2,1H3,(H,20,26)
|
| Chemical Name |
(2,5-dioxopyrrolidin-1-yl) 5-[[4-(6-methyl-1,2,4,5-tetrazin-3-yl)phenyl]methylamino]-5-oxopentanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
